Raymond Miralbell
Co-Founder
Terapet
Terapet has developed Qualγscan™, an end-to-end quality assurance device that enhances proton therapy by providing precise 3D dose measurement and imaging capabilities. This technology addresses the need for improved quality control in cancer treatment, ensuring accurate delivery of radiation to optimize patient outcomes.
- Biotechnology
- Medical Devices
Updated 23 months ago
Funding
Raised to date
$3.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Proton therapy, a precise form of radiation treatment for cancer, requires stringent quality control to ensure accurate dose delivery and minimize damage to healthy tissue. Existing quality assurance methods often lack the ability to provide comprehensive 3D dose verification, potentially leading to suboptimal treatment outcomes.
Solution
Terapet's Qualγscan™ is an end-to-end quality assurance device designed to enhance proton therapy through precise 3D dose measurement and imaging. This technology provides comprehensive quality control, ensuring accurate radiation delivery to the targeted tumor while minimizing exposure to surrounding healthy tissues. By offering detailed 3D dose verification, Qualγscan™ enables clinicians to optimize treatment plans and improve patient outcomes in proton therapy.
Target Audience
The primary users are radiation oncologists, medical physicists, and other healthcare professionals involved in proton therapy treatment planning and delivery at cancer centers and hospitals.
Features
- Provides precise 3D dose measurement for quality assurance in proton therapy.
- Enables comprehensive imaging capabilities for accurate radiation delivery.
- Facilitates the optimization of treatment plans to improve patient outcomes.
- Supports quality control in cancer treatment by ensuring accurate dose delivery.